MMS Offers $1M Award Toward COVID-19 Vaccine Development


Applied Clinical Trials

MMS Holdings (MMS), a data-focused CRO, is offering a $1 million award toward the development of a vaccine for COVID-19. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or with other global health authorities. Organizations interested in applying for this award can submit a notification of interest at

For more information, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.